用免疫疗法治疗的NSCLC患者的肠道抗体
Ewelina Iwan1, Anna Grenda2, Arkadiusz Bomba1
1Department of Omics Analyses, National Veterinary Research Institute, Pulawy, Poland.
Frontiers in genetics
|August 22, 2024
概括
在非小细胞肺癌患者中,肠道抗体组合因其对免疫治疗的反应而异. 肠道微生物群中的特定耐药性基因可以预测治疗疗效和患者生存结果.
科学领域:
- 在瘤学瘤学.
- 微生物组研究 微生物组研究
- 免疫治疗是一种免疫疗法.
背景情况:
- 针对编程细胞死亡1 (PD-1) 和编程细胞死亡联体1 (PD-L1) 的免疫疗法是非小细胞肺癌 (NSCLC) 的关键治疗方法.
- PD-L1是免疫治疗反应的不完美的预测指标,导致一些患者出现初级或二级耐药性.
- 了解影响免疫治疗疗效的因素对于改善患者的治疗结果至关重要.
研究的目的:
- 在接受免疫检查点抑制剂治疗的NSCLC患者中研究肠道抵抗体组成.
- 与临床特征相关联抗体概况,并确定免疫疗法疗效的潜在新预测因素.
主要方法:
- 使用有针对性的元基因组学分析了30名接受免疫治疗 (尼沃卢马布,布罗利祖马布或阿特佐利祖马布) 的高级NSCLC患者的肠道抗体.
- 患者包括19名男性和11名女性,接受一线或二线免疫疗法治疗.
主要成果:
- 耐药性丰富性因临床和人口因素而异,包括吸烟史.
- 疾病进展的患者表现出更丰富和多样化的抗体,具有更高水平的林科萨米德抗性基因 (例如,lnuC).
- 特定的耐药基因 (*lnuC*, *msrD*, *ermG*, *aph(6)*, *fosA*) 与无进展和整体存活相关.
结论:
- 肠道抗体组合在响应免疫治疗的NSCLC患者和不响应免疫治疗的患者之间有显著差异.
- 已识别的耐药性标志物表明在预测治疗疗效和患者存活率方面可能发挥作用.
- 对肠道抗体的进一步研究是有必要的,以优化NSCLC的免疫疗法策略.
更多相关视频
09:01Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
306
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.2K
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
Cytotoxic T Cells-mediated Immune Response
861
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
861
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154
